The Lung Research Center, LLC

Summary

The Lung Research Center, LLC is a medical facility located in Chesterfield, Missouri. This center is recognized for care of Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Fibrosing Alveolitis, Chronic Bronchitis, Chronic Cough and other specialties. The Lung Research Center, LLC is involved with conducting 29 clinical trials across 20 conditions. There are 1 research doctors associated with this hospital, such as Neil A Ettinger.

Top PIs

Clinical Trials running at The Lung Research Center, LLC

Idiopathic Pulmonary Fibrosis

Chronic Obstructive Pulmonary Disease

Bronchiectasis

Interstitial Lung Disease

BI 1015550

for Pulmonary Fibrosis

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.

Recruiting

2 awards

Phase 3

Inhaled Treprostinil

for Pulmonary Fibrosis

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

Recruiting

1 award

Phase 3

11 criteria

DWN12088

for Idiopathic Pulmonary Fibrosis

This trial is testing a new drug called DWN12088 to see if it can help people with Idiopathic Pulmonary Fibrosis, a serious lung disease. The study will check if the drug is safe and effective. The exact way the drug works is not detailed, but it aims to improve lung function or slow down the disease.

Recruiting

0 awards

Phase 2

8 criteria